Pharmacogenomics and drug response in cardiovascular disorders

Pharmacogenomics

Volumn 5, Issue 7, 2004, Pages 779-802

  Siest, Gerard ^a   Jeannesson, E ^a   Berrahmoune, H ^a   Maumus, S ^a   Marteau, J B ^a   Mohr, S ^a   Visvikis, S ^a  

^a INSERM   (France)

Author keywords

Cardiovascular diseases; Drug metabolizing enzymes; Environmental intervention; Pharmacodynamics; Pharmacogenomics; Pharmacokinetics; Physiological variability

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; APOLIPOPROTEIN E; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEZAFIBRATE; CARDIOVASCULAR AGENT; CHOLESTEROL 7ALPHA MONOOXYGENASE; CHOLESTEROL ESTER TRANSFER PROTEIN; CLOPIDOGREL; CYTOCHROME P450; CYTOCHROME P450 2C; CYTOCHROME P450 2D6; CYTOCHROME P450 3A; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DRUG METABOLIZING ENZYME; GLYCOPROTEIN IIIA; IRBESARTAN; LIPID; ORBOFIBAN; TICLOPIDINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AGE DISTRIBUTION; ANTICOAGULATION; BLEEDING; CARDIOVASCULAR DISEASE; CIGARETTE SMOKING; DIETARY INTAKE; DRUG CONJUGATION; DRUG METABOLISM; DRUG RESPONSE; DRUG TARGETING; DRUG TRANSPORT; ETHNIC DIFFERENCE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; LIPID BLOOD LEVEL; METABOLIC SYNDROME X; PHARMACODYNAMICS; PHARMACOGENOMICS; PHYSIOLOGY; REGULATORY MECHANISM; REVIEW; SEX DIFFERENCE;

ANIMALS; CARDIOTONIC AGENTS; CARDIOVASCULAR DISEASES; DRUG DELIVERY SYSTEMS; HUMANS; PHARMACOGENETICS;

EID: 6344233727     PISSN: 14622416     EISSN: None     Source Type: Journal    
DOI: 10.1517/14622416.5.7.779     Document Type: Review

References (127)

1. Siest G, Ferrari L, Accaoui MJ et al.: Pharmacogenomics of drugs affecting the cardiovascular system. Clin. Chem. Lab. Med. 41(4), 590-599 (2003).
2. Nelson DR, Zeldin DC, Hoffman SM et al.: Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. Pharmacogenetics 14(1), 1-18 (2004).
3. Wolf CR, Smith G: Pharmacogenetics. Br. Med. Bull. 55(2), 366-386 (1999).
4. Evans WE, Relling MV: Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286(5439), 487-491 (1999).
5. Pirmohamed M, Park K: Cytochrome P450 enzyme polymorphisms and adverse drug reactions. Toxicology 192(1), 23-32 (2003).
6. Linder MW, Prough RA, Valdes R Jr: Pharmacogenetics: a laboratory tool for optimizing therapeutic efficiency. Clin. Chem. 43(2), 254-266 (1997).
7. Zanger UM, Raimundo S, Eichelbaum M: Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiederbergs Arch. Pharmacol. 369(1), 23-37 (2004).
8. Cascorbi I: Pharmacogenetics of cytochrome P4502D6: genetic background and clinical implication. Eur. J. Clin. Invest. 33(2), 17-22 (2003).
9. Nakagawa K, Ishizaki T: Therapeutic relevance of pharmacogenetic factors in cardiovascular medicine. Pharmacol. Ther. 86(1), 1-28 (2000).
10. Takahashi H, Echizen H: Pharmacogenetics of warfarin elimination and its clinical implications. Clin. Pharmacokinet. 40(8), 587-603 (2001).
11. Steward DJ, Haining RL, Henne KR et al.: Genetic association between sensitivity to warfarin and expression of CYP2C9*3. Pharmacogenetics 7(5), 361-367 (1997).
12. Muck W: Clinical pharmacokinetics of cerivastatin. Clin. Pharmacokinet. 39(2), 99-116 (2000).
13. Burk O, Wojnowski L: Cytochrome P4503A and their regulation. Naunyn Schmiedebergs Arch. Pharmacol. 369(1), 105-124 (2004).
14. Kanathur N, Mathai MG, Byrd RP Jr et al.: Simvastatin-diltiazem drug interaction resulting in rhabdomyolysis and hepatitis. Tenn. Med. 94(9), 339-341 (2001).
15. Meisel C, Gerloff T, Kirchheiner J et al.: Implications of pharmacogenetics for individualizing drug treatment and for study design. J. Mol. Med. 81(3), 154-167 (2003).
16. Zschieschang P, Hiepe F, Gromnica-Ihle E, Roots I, Cascorbi I: Lack of association between arylamine N-acetyltransferase 2 (NAT2) polymorphism and systemic lupus erythematosus. Pharmacogenetics 12(7), 559-563 (2002).
17. Danoff TM, Campbell DA, McCarthy LC et al.: A Gilbert's syndrome UGT1A1 variant confers susceptibility to tranilast-induced hyperbilirubinemia. Pharmacogenomics J. 4(1), 49-53 (2004).
18. Glatt H, Meinl W: Pharmacogenetics of soluble sulfotransferases (SULTs). Naunyn Schmiedebergs Arch. Pharmacol. 369(1), 55-68 (2004).
19. Habdous M: [Place des glutathion S-transférases parmi les marqueurs biologiques de risques cardiovasculaires.] Doctorar de l'Université Henri Poincaré Nancy 1, France (2003).
20. Gerloff T: Impact of genetic polymorphisms in transmembrane carrier-systems on drug and xenobiotic distribution. Naunyn Schmiedebergs Arch. Pharmacol. 369(1), 69-77 (2004).
21. Shapiro LE, Shear NH: Drug interactions: Proteins, pumps, and P450s. J. Am. Acad. Dermatol. 47(4), 467-484 (2002).
22. Hoffmeyer S, Burk O, Von Richter O et al.: Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. USA 97(7), 3473-3478 (2000).
23. Humma LM, Terra SG: Pharmacogenetics and cardiovascular disease: impact on drug response and applications to disease management. Am. J. Heart Syst. Pharm. 59(13), 1241-1252 (2002).
24. Charron P, Komajda M: Are we ready for pharmacogenomics in heart failure? Eur. J. Pharmacol. 417(1-2), 1-9 (2001).
25. Feldman AM: The emerging role of pharmacogenomics in the treatment of patients with heart failure. Ann. Thorac. Surg. 76(6 , S2246-S2253 (2003).
26. Goldstein DB, Tate SK, Sisodiya SM: Pharmacogenetics goes genomic. Nat. Rev. Genet. 4(12), 937-947 (2003).
27. Mukherjee D, Topol EJ: Pharmacogenomics in cardiovascular diseases. Curr. Probl. Cardiol. 28(5), 317-347 (2003).
28. Tuddenham EGD: Association of thrombotic disease with genetic polymorphism of haemostatic genes: relevence to pharmacogenetics. In: Cardiovascular Pharmacogenetics (Vol. 160). Handbook of Experimental Pharmacology. Wilkins MR (Ed.), Springer-Verlag, Berlin Heidelberg, Germany 311-322 (2004).
29. Fuster V, Badimon L, Badimon JJ et al.: The pathogenesis of coronary artery disease and the acute coronary syndromes (1). N. Engl. J. Med. 326(4), 242-250 (1992).
30. Coller BS: Antiplatelet agents in the prevention and therapy of thrombosis. Ann. Rev. Med. 43, 171-180 (1992).
31. Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. Br. Med. J. 308(6921), 81-106 (1994).
32. Poggio ED, Kottke-Marchant K, Welsh PA et al.: The prevalence of aspirin resistance in cardiac patients as measured by platelet aggregation and the PFA-100. J. Am. Coll. Cardiol. 33(2, Suppl. A), 254A (1999).
33. Grotemeyer KH, Scharafinski HW, Husstedt IW: Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients. Thromb. Res. 71 (5), 397-403 (1993).
34. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S: Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 105(14), 1650-1655 (2002).
35. Hillarp A, Palmqvist B, Lethagen S, Villoutreix BO, Mattiasson I: Mutation within the cyclooxygenase-I gene in aspirin non-responders with recurrence of stroke. Thromb. Res. 112(5-6), 275-283 (2003).
36. Mansour-Chemaly M, Haddy N, Siest G, Visvikis S: Family studies: their role in the evaluation of genetic cardiovascular risk factors. Clin. Chem. Lab. Med. 40(11), 1085-1096 (2002).
37. A2 polymorphism: the Framingham Offspring Study. Arterioscler. Thromb. Vasc. Biol. 19(4), 1142-1147 (1999).
38. Walter DH, Schachinger V, Elsner M et al.: Platelet glycoprotein IIIa polymorphisms and risk of coronary stent thrombosis. Lancet 350(9086), 1217-1219 (1997).
39. Nurden AT: Platelet glycoprotein IIIa polymorphism and coronary thrombosis. Lancet 350(9086), 1189-1191 (1997).
40. A2 polymorphism and efficacy of aspirin. Lancet 351(9111), 1253 (1998).
41. A1/A2 polymorphism of platelet glycoprotein IIIa. Br. J. Haematol. 110(4), 965-967 (2000).
42. A2 polymorphism. Am. Heart J. 143(1), 76-82 (2002).
43. O'Connor FF, Shields DC, Fitzgerald A et al.: Genetic variation in glycoprotein IIb/IIIa (GPIIb/IIIa) as a determinant of the responses to an oral GPIIb/IIIa antagonist in patients with unstable coronary syndromes. Blood 98(12), 3256-3260 (2001).
44. A2,Zwb) positive platelets in patients with cardiovascular disease. Eur. Heart J. 20(10), 742-747 (1999).
45. A2 polymorphism in siblings of patients with premature coronary heart disease. Arch. Pathol. Lab. Med. 123(12), 1223-1229 (1999).
46. Feng D, Lindpaintner K, Larson MG et al.: Platelet glycoprotein IIIa Pl(a) polymorphism, fibrinogen, and platelet aggregability: the Framingham Heart Study. Circulation 104(2), 140-144 (2001).
47. Schomig A, Neumann FJ, Kastrati A et al.: A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N. Engl. J. Med. 334(17), 1084-1089 (1996).
48. Urban P, Macaya C, Rupprecht HJ et al.: Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS). Circulation 98(20), 2126-2132 (1998).
49. Geiger J, Brich J, Honig-Liedl P et al.: Specific impairment of human platelet P2Y(AC) ADP receptor-mediated signaling by the antiplatelet drug clopidogrel. Arterioscler. Thromb. Vasc. Biol. 19(8), 2007-2011 (1999).
50. Vormfelde SV, Burckhardt G, Zirk A et al.: Pharmacogenomics of diuretics drugs: data on rare monogenic disorders and on polymorphisms and requirements for further research. Pharmacogenomics 4(6), 701-734 (2003).
51. Maumus S: Hypolipemic drugs as a specific example of pharmacogenomics approach for cardiovascular risk. In preparation.
52. Roden DM: Pharmacogenetics and drug-induced arrhythmias. Cardiovasc. Res. 50(2), 224-231 (2001).
53. Baglia RR, Narula J: Pharmacogenomics of congestive heart failure. Med. Clin. North Am. 87(2), 569-578 (2003).
54. Bianchi G, Staessen JA, Ferrari P: Pharmacogenomics of primary hypertension - the lessons from the past to look toward the future. Pharmacogenomics 4(3), 279-296 (2003).
55. Cadman PE, O'Connor DT: Pharmacogenomics of hypertension. Curr. Opin. Nephrol. Hypertens. 12(1), 61-70 (2003).
56. Arnett DK, Boerwinkle E, Davis BR, Eckfeldt J, Ford CE, Black H: Pharmacogenetic approaches to hypertension therapy: design and rationale for the Genetics of Hypertension Associated Treatment (GenHAT) study. Pharmacogenomics J. 2(5), 309-317 (2002).
57. Marteau JB, Zaiou M, Pfister M et al.: Genetic variations associated with blood pressure and hypertension: an overview. J. Hyperten. (2004) (Submitted).
58. International Statistical Classification of Diseases and Related Health Problems, 1989 Revision. World Health Organization, Geneva (1992).
59. Reaven GM: Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37(12), 1595-1607 (1988).
60. Ginsberg HN: Treatment for patients with the metabolic syndrome. Am. J. Cardiol. 91(7A), 29E-39E (2003).
61. Jonas M, Reicher-Reiss H, Boyko V et al.: Usefulness of β-blocker therapy in patients with non-insulin-dependent diabetes mellitus and coronary artery disease. Bezafibrate Infarction Prevention (BIP) Study Group. Am. J. Cardiol. 77(15), 1273-7 (1996).
62. McNamara DM, Holubkov R, Janosko K et al.: Pharmacogenetic interactions between β-blocker therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure. Circulation 103(12), 1644-1648 (2001).
63. Sofowora GG, Dishy V, Muszkat M et al.: A common β1-adrenergic receptor polymorphism (Arg389Gly) affects blood pressure response to β-blockade. Clin. Pharmacol. Ther. 73(4 , 366-371 (2003).
64. 1-Adrenergic receptor polymorphisms and antihypertensive response to metoprolol. Clin. Pharmacol. Ther. 74(1), 44-52 (2003).
65. Ferrari P, Bianchi G: Genetic mapping and tailored antihypertensive therapy. Cardiovasc. Drugs Ther. 14(4), 387-95 (2000).
66. Liljedahl U, Karlsson J, Melhus H et al.: A microarray minisequencing system for pharmacogenetic profiling of antihypertensive drug response. Pharmacogenetics 13(1), 7-17 (2003).
67. Kurland L: The antihypertensive response to irbesartan treatment from a pharmacogenetic perspective. Minerva Med. 94(4), 251-258 (2003).
68. Bluher M, Lubben G, Paschke R: Analysis of the relationship between the Pro12Ala variant in the PPAR-γ2 gene and the response rate to therapy with pioglitazone in patients with Type 2 diabetes. Diabetes Care 26(3), 825-831 (2003).
69. Qi N, Kazdova L, Zidek V et al.: Pharmacogenetic evidence that cd36 is a key determinant of the metabolic effects of pioglitazone. J. Biol. Chem. 277(50), 48501-48507 (2002).
70. Abbasi F, Chu JW, McLaughlin T et al.: Effect of metformin treatment on multiple cardiovascular disease risk factors in patients with Type 2 diabetes mellitus. Metabolism 53(2), 159-164 (2004).
71. Kirchheiner J, Brockmoller J, Meineke I et al.: Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers. Clin. Pharmacol. Ther. 71(4), 286-296 (2002).
72. Maidand-van der Zee AH, Klungel OH, Stricker BH et al.: Genetic polymorphisms: importance for response to HMG-CoA reductase inhibitors. Atherosclerosis 163(2), 213-222 (2002).
73. Hoffmann MM, Winkelmann BR, Wieland H, März W: Pharmacogenomics of lipid-lowering agents. In: Pharmacogenomics: The Search for Individualized Therapies. Julio Licinio, Ma-Li Wong (Eds), Wiley-VCH, Weinheim, Germany 267-281 (2002).
74. Ordovas JM, Shen H: Pharmacogenetics of lipid-lowering therapies. Curr. Atheroscler. Rep. 4(3), 183-192 (2002).
75. Schmitz G, Drobnik W: Pharmacogenomics and pharmacogenetics of cholesterol-lowering therapy. Clin. Chem. Lab. Med. 41(4), 581-589 (2003).
76. Winkelmann BR, Hoffmann MM, März W: Lipid-lowering responses modified by genetic variation. In: Cardiovascular Pharmacogenetics (Vol. 160). Handbook of Experimental Pharmacology. Wilkins MR (Ed.), Springer-Verlag, Berlin/Heidelberg, Germany 107-147 (2004).
77. Siest G, Bertrand P, Herbeth B et al.: Apolipoprotein E polymorphisms and concentration in chronic diseases and drug responses. Clin. Chem. Lab. Med. 38(9), 841-852 (2000).
78. Kuivenhoven JA, Jukema JW, Zwinderman AH et al.: The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group. N. Engl. J. Med. 338(2), 86-93 (1998).
79. Carlquist JF, Muhlestein JB, Horne BD et al.: The cholesteryl ester transfer protein Taq1B gene polymorphism predicts clinical benefit of statin therapy in patients with significant coronary artery disease. Am. Heart J. 146(6), 1007-1014 (2003).
80. Van Venrooij FV, Stolk RP, Banga JD et al.: DALI Study Group. Common cholesteryl ester transfer protein gene polymorphisms and the effect of atorvastatin therapy in Type 2 diabetes. Diabetes Care 26(4), 1216-1223 (2003).
81. Ordovas JM, Lopez-Miranda J, Perez-Jimenez F et al.: Effect of apolipoprotein E and A-IV phenotypes on the low density lipoprotein response to HMG CoA reductase inhibitor therapy. Atherosclerosis 113(2), 157-166 (1995).
82. Gerdes LU, Gerdes C, Kervinen K et al.: The apolipoprotein E4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction: a substudy of the Scandinavian simvastatin survival study. Circulation 101(12), 1366-1371 (2000).
83. Garcia-Otin AL, Civeira F, Aristegui R et al.: ATOMIX Study Group. Atorvastatin in Mixed dyslipidemia. Allelic polymorphism -491A/T in apo E gene modulates the lipid-lowering response in combined hyperlipidemia treatment. Eur. J. Clin. Invest. 32(6), 421-428 (2002).
84. Jukema JW, van der Hoorn JW: Amlodipine and atorvastatin in atherosclerosis: a review of the potential of combination therapy. Expert Opin. Pharmacother. 5(2), 459-468 (2004).
85. Siest G, Visvikis S, Herbeth B et al.: Objectives, design and recruitment of a familial and longitudinal cohort for studying gene-environment interactions in the field of cardiovascular risk: the Stanislas Cohort. Clin. Chem. Lab. Med. 36(1), 35-42 (1998).
86. Brownley KA, Hurwitz BE, Schneiderman N: Ethnic variations in the pharmacological and nonpharmacological treatment of hypertension: biopsychosocial perspective. Hum. Biol. 71(4), 607-639 (1999).
87. Kalow W: Interethnic variation of drug metabolism. Trends Pharmacol. Sci. 12(3), 102-107 (1991).
88. Renwick AG: Inter-ethnic differences in xenobiotic metabolism. Environ. Toxicol. Pharmacol. 2(2-3), 165-170 (1996).
89. Tomlinson B: Pharmacokinetic and pharmacodynamic responses to cardiovascular drugs in Asians. Acta Pharmacol. Sin. 19(Suppl.), 12-13 (1998).
90. Sachse C, Brockmoller J, Bauer S, Roots I: Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am. J. Hum. Genet. 60(2), 284-295 (1997).
91. Evans WE, Johnson JA: Pharmacogenomics: the inherited basis for interindividual differences in drug response. Ann. Rev. Genomics Hum. Genet. 2, 9-39 (2001).
92. Kalow W: Pharmacogenetics, pharmacogenomics, and pharmacobiology. Clin. Pharmacol. Ther. 70(1), 1-4 (2001).
93. Siest G, Schlenck A, Starck M, Vincent-Viry M, Schiele F, Visvikis S: Apolipoprotein E: laboratory determinations and clinical interest. In: Handbook of Lipoprotein Testing. Chapter 19. Rifai N, Warnick GR, Dominiczak MH, (Eds), AACC Press, Washington DC, USA 401-440 (2000).
94. Gerdes LU, Klausen IC, Sihm I, Faergeman O: Apolipoprotein E polymorphism in a Danish population compared to findings in 45 other study populations around the world. Genet. Epidemiol. 9(3), 155-167 (1992).
95. Tiret L, de Knijff P, Menzel HJ, Ehnholm C, Nicaud V, Havekes LM: ApoE polymorphism and predisposition to coronary heart disease in youths of different European populations. The EARS Study. European Atherosclerosis Research Study. Arterioscler. Thromb. 14(10), 1617-1624 (1994).
96. Podrazik PM, Schwartz JB: Cardiovascular pharmacology of aging. Cardiol. Clin. 17(1), 17-34 (1999).
97. Schwartz JB: Gender-specific implications for cardiovascular medication use in the elderly optimizing therapy for older women. Cardiol. Rev. 11(5), 275-298 (2003).
98. Krecic-Shepard ME, Park K, Barnas C, Slimko J, Kerwin DR, Schwartz JB: Race and sex influence clearance of nifedipine: results of a population study: Clin. Pharmacol. Ther. 68(2),130-142 (2000).
99. Kang D, Verotta D, Krecic-Shepard ME, Modi NB, Gupta SK, Schwartz JB: Population analyses of sustained-release verapamil in patients: effects of sex, race, and smoking. Clin. Pharmacol. Ther. 73(1), 31-40 (2003).
100. Schwartz JB: The influence of sex on pharmacokinetics. Clin. Pharmacokinet. 42(2), 107-121 (2003).
101. Castellano M, Rossi F, Giacche M et al.: β(2)-Adrenergic receptor gene polymorphism, age, and cardiovascular phenotypes. Hypertension 41(2), 361-367 (2003).
102. Drysdale CM, McGraw DW, Stack CB et al.: Complex promoter and coding region β2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc. Natl. Acad. Sci. USA 97(19), 10483-10488 (2000).
103. Dishy V, Sofowora GG, Xie HG et al.: The effect of common polymorphisms of the β2-adrenergic receptor on agonist-mediated vascular desensitization. N. Engl. J. Med. 345(14), 1030-1035 (2001).
104. Sing CF, Haviland MB, Reilly SL: Genetic architecture of common mutifactorial diseases. Ciba Foundation Symposium 197, 211-232 (1996).
105. Hubacek JA, Pitha J, Skodova Z et al.: Czech MONICA Study. Polymorphisms in CYP-7A1, not APOE, influence the change in plasma lipids in response to population dietary change in an 8 year follow-up; results from the Czech MONICA study. Clin. Biochem. 36(4), 263-267 (2003).
106. Ordovas JM, Mooser V: The APOE locus and the pharmacogenetics of lipid response. Curr. Opin. Lipidol. 13(2), 113-117 (2002).
107. Schein JR: Cigarette smoking and clinically significant drug interactions. Ann. Pharmacother. 29(11), 1139-1148 (1995).
108. Pezzini A, Grassi M, Dei Zotto E et al.: Synergistic effect of apolipoprotein E polymorphisms and cigarette smoking on risk of ischemic stroke in young adults. Stroke 35(2), 438-442 (2004).
109. Humphries SE, Talmud PJ, Hawe E, Bolla M, Day IN, Miller GJ: Apolipoprotein E4 and coronary heart disease in middle-aged men who smoke: a prospective study. Lancet 358, 115-119 (2001).
110. Djousse L, Myers RH, Province MA et al.: Influence of apolipoprotein E, smoking, and alcohol intake on carotid artery intima-media thickness: the NHLBI Family Heart Study. Stroke 33, 1357-1361 (2002).
111. Mooser V, Waterworth DM, Isenhour T, Middleton L: Cardiovascular pharmacogenetics in the SNP era. J. Thromb. Haemost. 1(7), 1398-1402 (2003).
112. Anderson JL, Carlquist JF, Horne BD, Muhlestein JB: Cardiovascular pharmacogenomics: current status, future prospects. J. Cardiovasc. Pharmacol. Ther. 8(1), 71-83 (2003).
113. Terra SG, Johnson JA: Pharmacogenetics, pharmacogenomics, and cardiovascular therapeutics: the way forward. Am. J. Cardiovasc. Drugs 2(5), 287-296 (2002).
114. Goldstein DB, Ahmadi KR, Weale ME, Wood NW: Genome scans and candidate gene approaches in the study of common diseases and variable drug responses. Trends Genet. 19(11), 615-622 (2003).
115. Quinn MJ, Topol EJ: Common variations in platelet glycoproteins: pharmacogenomic implications. Pharmacogenomics 2(4 , 341-352 (2001).
116. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP: Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 270(1), 414-423 (1994).
117. Abernethy DR, Flockhart DA: Molecular basis of cardiovascular drug metabolism: implications for predicting clinically important drug interactions. Circulation 101(14), 1749-1753 (2000).
118. Lee CR, Goldstein JA, Pieper JA: CYP 2C9 polymorphisms: a comprehensive review of the in vitro and human data. Pharmacogenetics 12(3), 251-263 (2002).
119. Daly AK: Pharmacogenetics of the major polymorphic metabolizing enzymes. Fundam. Clin. Pharmacol. 17(1), 27-41 (2003 ).
120. Yamazaki H, Shibata A, Suzuki M et al.: Oxidation of troglitazone to a quinone-type metabolite catalyzed by cytochrome P450 2C8 and P450 3A4 in human liver microsomes. Drug Metab. Dispos. 27(11), 1260-1266 (1999).
121. Lewis DFV: Guide to Cytochrome P450 Structure and Function Taylor and Francis, UK (2001).
122. Vidal Dictionary. Editions du Vidal, Paris (2003).
123. Kodakimble MA, Young LY: Applied therapeutics. In: The Clinical Use of Drugs (7th edn). Kodakimble MA, Young LY (Eds), San Francisco, CA, USA (2001).
124. Miners JO, Birkett DJ: Cytochrome P450 2C9: an enzyme of major importance in human drug metabolism. Br. J. Clin. Pharmacol. 45(6), 525-538 (1998).
125. Fromm MF: The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans. Adv. Drug Deliv. Rev. 54(10), 1295-1310 (2002).
126. Michelson AD, Furman MI, Goldschmidt-Clermont P et al.: Platelet GP IIIa PI(A) polymorphisms display different sensitivities to agonists. Circulation 101(9), 1013-1018 (2000).
127. Vijayan KV, Goldschmidt-Clermont PJ, Roos C, Bray PF: The Pl(A2) polymorphism of integrin β(3) enhances outside-in signaling and adhesive functions. J. Clin. Invest. 105(6), 793-802 (2000).